SITE012-0110

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-07-01

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 60); relationship: Y

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-14 (study day 360); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-17 (study day 363); relationship: not assessed

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-02-14 (study day 575); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-10-02 (study day 806); relationship: not assessed

severe serious reported

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-11-13 (study day 848); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.